Demographic and biologic characteristics of 84 elderly adults with newly diagnosed AML treated with tipifarnib plus etoposide
| Characteristic . | Value . |
|---|---|
| Sex, n (%) | |
| Male | 40 (48) |
| Female | 44 (52) |
| Median age, y (range) | 77 (70-91) |
| Biologic disease features | |
| Secondary AML | 46 (55%) |
| MDS/AML | 36 |
| Treatment-related AML | 10 |
| Prior MDS therapy | 16/46 (35%)* |
| Adverse cytogenetics | 43 (of 79 performed, 54%) |
| Single −5 or −7 | 7 |
| Complex (> 3 lesions) | 27 |
| FLT-3 ITD (normal cytogenetics) | 6 |
| Median pretreatment peripheral blood WBC (range) | 5200/μL (300-226 000) |
| Blasts > 10 000/μL | 26 (31%) |
| Pretreatment hydroxyurea (blasts > 30 000/μL) | 15 (18%) |
| Median pretreatment marrow blast percentage (range) | 55% (18%-96%) |
| Patients with > 1 poor-risk disease feature, n (%) | 66 (79%) |
| Host comorbidities, no. of patients | |
| Cardiovascular | 30 |
| Pulmonary | 17 |
| Gastrointestinal | 13 |
| Renal | 13 |
| Diabetes | 12 |
| Neurologic (central) | 11 |
| More than 2 prior malignancies | 22 (6) |
| More than 1 comorbidity | 76 (90%) |
| More than 3 comorbidities | 35 (42%) |
| Characteristic . | Value . |
|---|---|
| Sex, n (%) | |
| Male | 40 (48) |
| Female | 44 (52) |
| Median age, y (range) | 77 (70-91) |
| Biologic disease features | |
| Secondary AML | 46 (55%) |
| MDS/AML | 36 |
| Treatment-related AML | 10 |
| Prior MDS therapy | 16/46 (35%)* |
| Adverse cytogenetics | 43 (of 79 performed, 54%) |
| Single −5 or −7 | 7 |
| Complex (> 3 lesions) | 27 |
| FLT-3 ITD (normal cytogenetics) | 6 |
| Median pretreatment peripheral blood WBC (range) | 5200/μL (300-226 000) |
| Blasts > 10 000/μL | 26 (31%) |
| Pretreatment hydroxyurea (blasts > 30 000/μL) | 15 (18%) |
| Median pretreatment marrow blast percentage (range) | 55% (18%-96%) |
| Patients with > 1 poor-risk disease feature, n (%) | 66 (79%) |
| Host comorbidities, no. of patients | |
| Cardiovascular | 30 |
| Pulmonary | 17 |
| Gastrointestinal | 13 |
| Renal | 13 |
| Diabetes | 12 |
| Neurologic (central) | 11 |
| More than 2 prior malignancies | 22 (6) |
| More than 1 comorbidity | 76 (90%) |
| More than 3 comorbidities | 35 (42%) |
Prior MDS therapy: 7, growth factors alone; 9, 5-azacytidine/decitabine or thalidomide/lenalidamide.